Abstract

This clinical study validates an early treatment window for predicting complete or near-complete pathological response of breast cancer patients based on pretreatment total-hemoglobin level (THb), early changes of THb and ultrasound measurements following neoadjuvant chemotherapy.

© 2020 The Author(s)

PDF Article